We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fostamatinib combined with TPO‐RAs or steroids as a bridge to monotherapy or as time‐limited continuous treatment in relapsed chronic ITP: A single‐centre case series.
- Authors
Passucci, Mauro; Laganà, Alessandro; Donzelli, Livia; Masucci, Chiara; Genoese, Angelo; Chistolini, Antonio; Baldacci, Erminia; Santoro, Cristina
- Abstract
This article discusses the use of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in combination with other treatments for relapsed chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorder characterized by low platelet counts. The study analyzed 15 adult patients who received fostamatinib in combination with prednisone or thrombopoietin receptor agonists (TPO-RAs). The results showed that the combination therapy was effective in achieving a response in 80% of patients, with 73% achieving a complete response. The treatment was generally well-tolerated, with no severe adverse events reported. However, further research is needed to determine the optimal schedule and feasibility of these combinations.
- Subjects
THROMBOPOIETIN receptor agonists; DRUG accessibility; INFORMED consent (Medical law); CLINICAL trials
- Publication
British Journal of Haematology, 2024, Vol 204, Issue 5, p2129
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19450